These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12871494)

  • 21. Fibrin γ/γ' influences the secretion of fibrinolytic components and clot structure.
    Cantero M; Rojas H; Anglés-Cano E; Marchi R
    BMC Mol Cell Biol; 2019 Nov; 20(1):47. PubMed ID: 31675913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly.
    Mosesson MW
    Blood Coagul Fibrinolysis; 1997 Jul; 8(5):257-67. PubMed ID: 9282789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrinogen and fibrin.
    Weisel JW
    Adv Protein Chem; 2005; 70():247-99. PubMed ID: 15837518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains.
    Siebenlist KR; Mosesson MW; Hernandez I; Bush LA; Di Cera E; Shainoff JR; Di Orio JP; Stojanovic L
    Blood; 2005 Oct; 106(8):2730-6. PubMed ID: 16002430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Position of gamma-chain carboxy-terminal regions in fibrinogen/fibrin cross-linking mixtures.
    Siebenlist KR; Meh DA; Mosesson MW
    Biochemistry; 2000 Nov; 39(46):14171-5. PubMed ID: 11087365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
    Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in clinical fibrinolysis.
    Hessel LW; Kluft C
    Clin Haematol; 1986 May; 15(2):443-63. PubMed ID: 2942332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen).
    Ritchie H; Lawrie LC; Crombie PW; Mosesson MW; Booth NA
    J Biol Chem; 2000 Aug; 275(32):24915-20. PubMed ID: 10816585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation.
    Mosesson MW
    Thromb Haemost; 2003 Jan; 89(1):9-12. PubMed ID: 12540947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of thrombin-catalyzed fibrin polymerization and factor XIIIa-catalyzed cross-linking of fibrin among three recombinant variant fibrinogens, gamma 275C, gamma 275H, and gamma 275A.
    Hirota-Kawadobora M; Terasawa F; Suzuki T; Tozuka M; Sano K; Okumura N
    J Thromb Haemost; 2004 Aug; 2(8):1359-67. PubMed ID: 15304042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking.
    Souri M; Osaki T; Ichinose A
    J Biol Chem; 2015 May; 290(19):12027-39. PubMed ID: 25809477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [From fibrinogen to fibrin and its dissolution].
    Juhan-Vague I; Hans M
    Bull Acad Natl Med; 2003; 187(1):69-82; discussion 83-4. PubMed ID: 14556455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonclottable fibrin obtained from partially reduced fibrinogen: characterization and tissue plasminogen activator stimulation.
    Procyk R; Medved L; Engelke KJ; Kudryk B; Blombäck B
    Biochemistry; 1992 Mar; 31(8):2273-8. PubMed ID: 1540582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the factors contributing to fibrin-dependent plasminogen activation.
    Mosesson MW; Siebenlist KR; Voskuilen M; Nieuwenhuizen W
    Thromb Haemost; 1998 Apr; 79(4):796-801. PubMed ID: 9569195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrin clot structure and mechanics associated with specific oxidation of methionine residues in fibrinogen.
    Weigandt KM; White N; Chung D; Ellingson E; Wang Y; Fu X; Pozzo DC
    Biophys J; 2012 Dec; 103(11):2399-407. PubMed ID: 23283239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelets and soluble fibrin promote plasminogen activation causing downregulation of platelet glycoprotein Ib/IX complexes: protection by aprotinin.
    de Haan J; van Oeveren W
    Thromb Res; 1998 Nov; 92(4):171-9. PubMed ID: 9840026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrin-mediated plasminogen activation.
    Nieuwenhuizen W
    Ann N Y Acad Sci; 2001; 936():237-46. PubMed ID: 11460481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.